XRTXF

Xortx Therapeutics (QB) Stock Price

0.1094
0.00 (0.0%)
0.1094
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Xortx Therapeutics Inc (QB) XRTXF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.1094 16:04:24
Close Price Low Price High Price Open Price Previous Close
0.1094 0.1094
Bid Price Ask Price Spread News
0.0712 1.10 1.03 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.1094 USD

Xortx Therapeutics (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 8.88M 81.18M 53.26M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
95.00 $ - 0.00% - -

more financials information »

Xortx Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical XRTXF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.10940.10940.10940.10942,0000.000.0%
1 Month0.115690.12470.10570.115479722,158-0.00629-5.44%
3 Months0.14140.20490.10570.156311231,743-0.032-22.63%
6 Months0.0850.250.0850.14562217,9290.024428.71%
1 Year0.16940.299950.075650.141729915,383-0.06-35.42%
3 Years0.14320.299950.075650.141045114,225-0.0338-23.6%
5 Years0.14320.299950.075650.141045114,225-0.0338-23.6%

Xortx Therapeutics (QB) Description

XORTX Therapeutics Inc. is a biopharmaceutical company with three clinically advanced products in development - XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 is a clinical stage program for Type 2 Diabetic Nephropathy (T2DN). The Company has strong intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.


Your Recent History
USOTC
XRTXF
Xortx Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.